Shots:

• The ongoing P-I/II study is evaluating the safety- tolerability- and immunogenicity of escalating dose levels of BNT162b1 (10µg & 30µg/ 100 µg) vs PBO in 45 adults aged 18-55yrs.
• Results: @28days (7days after dose 2)- neutralizing GMTs (168 & 267) corresponding to 1.8- and 2.8-times GMT of the convalescent serum panel; elevated RBD-binding IgG antibodies with GMCs (4-813 & 27-872 units/ml) which are 8- and 46.3-times- the GMC of 602 units/ml in a panel of 38 sera of convalescent patients who had contracted SARS-CoV-2
• The ongoing P-I/II study of four vaccine candidates will enable selection of a lead candidate and dose level for P-IIb/III study- expected to be initiated in Jul’2020. If vaccine get approval- the companies are expecting to manufacture up to 100M doses by the end of 2020 and more than 1.2B by the end of 2021

Click here to read full press release/ article | Ref: Pfizer | Image: Pharmashots

Related News: Pfizer and BioNTech Report First Patient Dosing with BNT162 in P-I/II Study for COVID-19 in the US